Overview Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD Status: Completed Trial end date: 2018-10-17 Target enrollment: Participant gender: Summary This study will evaluate the efficacy and safety of high doses of SPN 812 in children with ADHD Phase: Phase 3 Details Lead Sponsor: Supernus Pharmaceuticals, Inc.